[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component


Description

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

Trial Eligibility

Inclusion Criteria: * History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2) * Measurable multiple myeloma (MM) * Eastern Cooperative Oncology Group performance status of 0-1 Exclusion Criteria: * Condition that confounds the ability to interpret data from the study * Known active or history of central nervous system (CNS) involvement of MM Note: Other protocol-defined inclusion/exclusion criteria apply

Study Info

Organization

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company


Primary Outcome

Incidence of adverse events (AEs)


Outcome Timeframe Up to 2 years

NCTID NCT06121843

Phases PHASE1

Primary Purpose TREATMENT

Start Date 2024-02-22

Completion Date 2028-08-01

Enrollment Target 111

Interventions

DRUG BMS-986393

DRUG Alnuctamab

DRUG Mezigdomide

DRUG Iberdomide

Locations Recruiting

University of Alabama at Birmingham

United States, Alabama, Birmingham


Local Institution - 0002

United States, Arizona, Phoenix


City of Hope Comprehensive Cancer Center

United States, California, Duarte


Local Institution - 0005

United States, Florida, Jacksonville


Northside Hospital

United States, Georgia, Atlanta


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
Pfizer
Genentech
Regeneron
Adaptive

Follow Us

facebook instagram linkedin tiktok youtube